Evidence map›Paper›PMID 36248811›Full record

ArticleFrontiers in immunology2022

Lymphocyte-C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission.

Jian-Nan Zhang, Yang Gao, Xin-Tong Wang, Na-Na Li, Xue Du, Yu-Jia Tang, Qi-Qi Lai, Peng-Fei Chen, Chuang-Shi Yue, Ji-Han Wu and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jian-Nan ZhangDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Yang GaoDepartment of Critical Care Medicine, The Sixth Affiliated Hospital of Harbin Medical University, Harbin, China.
Xin-Tong WangDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Na-Na LiDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Xue DuDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Yu-Jia TangDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Qi-Qi LaiDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Peng-Fei ChenDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Chuang-Shi YueDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Ji-Han WuDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Kai KangDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Ming-Yan ZhaoDepartment of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we aimed to explore whether lymphocyte-C-reactive protein ratio (LCR) can differentiate disease severity of coronavirus disease 2019 (COVID-19) patients and its value as an assistant screening tool for admission to hospital and intensive care unit (ICU). A total of 184 adult COVID-19 patients from the COVID-19 Treatment Center in Heilongjiang Province at the First Affiliated Hospital of Harbin Medical University between January 2020 and March 2021 were included in this study. Patients were divided into asymptomatic infection group, mild group, moderate group, severe group, and critical group according to the Diagnosis and Treatment of New Coronavirus Pneumonia (ninth edition). Demographic and clinical data including gender, age, comorbidities, severity of COVID-19, white blood cell count (WBC), neutrophil proportion (NEUT%), lymphocyte count (LYMPH), lymphocyte percentage (LYM%), red blood cell distribution width (RDW), platelet (PLT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (SCr), albumin (ALB), total bilirubin (TB), direct bilirubin (DBIL), indirect bilirubin (IBIL), and D-dimer were obtained and collated from medical records at admission, from which sequential organ failure assessment (SOFA) score and LCR were calculated, and all the above indicators were compared among the groups. Multiple clinical parameters, including LYMPH, CRP, and LCR, showed significant differences among the groups. The related factors to classify COVID-19 patients into moderate, severe, and critical groups included age, number of comorbidities, WBC, LCR, and AST. Among these factors, the number of comorbidities showed the greatest effect, and only WBC and LCR were protective factors. The area under the receiver operating characteristic (ROC) curve of LCR to classify COVID-19 patients into moderate, severe, and critical groups was 0.176. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 1,780.7050 and 84.6% and 66.2%, respectively. The related factors to classify COVID-19 patients into severe and critical groups included the number of comorbidities, PLT, LCR, and SOFA score. Among these factors, SOFA score showed the greatest effect, and LCR was the only protective factor. The area under the ROC curve of LCR to classify COVID-19 patients into severe and critical groups was 0.106. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 571.2200 and 81.3% and 90.0%, respectively. In summary, LCR can differentiate disease severity of COVID-19 patients and serve as a simple and objective assistant screening tool for hospital and ICU admission.

Indexed as

COVID-19COVID-19 Drug TreatmentAdultAlanine TransaminaseAspartate AminotransferasesBilirubinC-Reactive ProteinCreatinineHospitalsHumansIntensive Care UnitsLymphocytesSeverity of Illness IndexAlanine TransaminaseAspartate AminotransferasesBilirubinC-Reactive ProteinCreatinineCOVID-19disease severityhospital admissionICU admissionlymphocyte–C-reactive protein ratioSARS-CoV-2 infectionscreening tool

Identifiers

PMID36248811
PMCPMC9554799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.